Table 1.
Patient and tumor characteristics.
| Characteristics | (n=444) |
|---|---|
| Age, year | |
| median (IQR) | 70.3 (65.5-74.4) |
| iPSA, ng/mlL | |
| median (IQR) | 7.1(5.6-10.4) |
| Gland size, cm 3 | |
| median (IQR) | 46.7 (35.1-65.1) |
| IUSP Grade, n (%) | |
| Group 1 (3+3) | 70 (15.8) |
| Group 2 (3+4) | 234 (52.7) |
| Group 3 (4+3) | 103 (23.2) |
| Group 4 (4+4) | 29 (6.5) |
| Group 5 (4+5) | 8 (1.8) |
| T-stage, n (%) | |
| Tlc | 28 (6.3) |
| T2a | 106 (23.9) |
| T2b | 124 (27.9) |
| T2c | 182 (41.0) |
| NCCN Risk, n (%) | |
| Low | 18 (4.1) |
| Favorable intermediate | 103 (23.2) |
| Unfavorable intermediate | 270 (60.8) |
| High | 53 (11.9) |
| ADT n (%) | 162 (36.4) |
PSA, Prostate Specific Antigen; iPSA, initial PSA; ADT, androgen deprivation therapy; IQR, interquartile range; mo, months.